Positive association between leptin serum levels and disease activity on endoscopy in inflammatory bowel disease: A case-control study

Trejo‑Vazquez,Fabiola; Garza‑Veloz,Idalia; Villela‑Ramirez,Gabriela   Alejandra; Ortiz‑Castro,Yolanda; Mauricio‑Saucedo,Panfilo; Cardenas‑Vargas,Edith; Diaz‑Baez,Mariana; Cid‑Baez,Miguel  A.; Castañeda‑Miranda,Rodrigo; Ortiz‑Rodriguez,Jose   Manuel; Solis‑Sanchez,Luis   Octavio; Martinez‑Fierro,Margarita  L.

doi:10.3892/etm.2018.5835

Positive association between leptin serum levels and disease activity on endoscopy in inflammatory bowel disease: A case-control study

Authors:
- Fabiola Trejo‑Vazquez
- Idalia Garza‑Veloz
- Gabriela Alejandra Villela‑Ramirez
- Yolanda Ortiz‑Castro
- Panfilo Mauricio‑Saucedo
- Edith Cardenas‑Vargas
- Mariana Diaz‑Baez
- Miguel A. Cid‑Baez
- Rodrigo Castañeda‑Miranda
- Jose Manuel Ortiz‑Rodriguez
- Luis Octavio Solis‑Sanchez
- Margarita L. Martinez‑Fierro
View Affiliations

Affiliations: Molecular Medicine Laboratory, Unidad Academica de Medicina Humana y Ciencias de la Salud, Universidad Autonoma de Zacatecas ‘Francisco García Salinas’, Zacatecas 98160, Mexico, Department of Gastroenterology, Hospital General de Zacatecas, Instituto de Seguridad y Servicios Sociales Para Los Trabajadores del Estado, Zacatecas 98000, Mexico, Bioengineering Laboratory, Unidad Academica de Ingenieria Electrica, Universidad Autonoma de Zacatecas, Zacatecas 98000, Mexico
Published online on: February 5, 2018 https://doi.org/10.3892/etm.2018.5835
Pages: 3336-3344
Copyright: © Trejo‑Vazquez et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Inflammatory bowel disease (IBD) includes ulcerative colitis (UC), Crohn's disease (CD) and indeterminate colitis. As these subtypes of IBD display important differences in the behavior of the natural course of the disease, the identification of non‑invasive markers for IBD is important. The aim of the present study was to evaluate the serum levels of 10 adipokines and their association with endoscopic activity in IBD. The 10‑protein profile (C‑peptide, ghrelin, gastric inhibitory polypeptide, glucagon‑like peptide‑1, glucagon, insulin, leptin, plasminogen activator inhibitor‑1, resistin and visfatin) was evaluated using serum from 53 participants (23 UC and 11 CD patients, as well as 19 controls) from Zacatecas (Mexico) by using the Bio‑Plex Pro Human Diabetes 10‑Plex Panel (Bio‑Rad Laboratories, Inc.). Compared with those in the controls, leptin levels were significantly lower in patients with IBD (P=4.9x10‑4). In addition, serum leptin displayed differences between groups with and without disease activity on endoscopy (P<0.001). Among the study population, serum leptin levels of <5,494 pg/ml significantly increased the odds of IBD by 12.8‑fold [odds ratio (OR)=12.8, 95% confidence interval (CI)=3.04‑53.9, P=0.001]. In addition, patients with serum leptin levels of <2,498 pg/ml displayed 5.8‑fold greater odds of disease activity on endoscopy among the study population (OR=5.8, 95% CI=1.52‑22.4, P=0.013). No differences in the serum levels of the remaining proteins were identified between the groups. Among the study population, serum leptin was associated with an increased risk of IBD and with disease activity on endoscopy. Additional studies will be necessary to validate the use of leptin as a non‑invasive biomarker of IBD severity.

View Figures

View References

1	Kuna AT: Serological markers of inflammatory bowel disease. Biochem Med (Zagreb). 23:28–42. 2013. View Article : Google Scholar : PubMed/NCBI
2	Yamamoto-Furusho JK: Clinical epidemiology of ulcerative colitis in Mexico: A single hospital-based study in a 20-year period (1987–2006). J Clin Gastroenterol. 43:221–224. 2009. View Article : Google Scholar : PubMed/NCBI
3	Cronica, . In Mexico there was a triple increase in the number of cases of inflammatory bowel disease. http://www.cronica.com.mx/notas/2017/1015339.html(In Spanish). July 21–2017
4	Cosnes J, Gower-Rousseau C, Seksik P and Cortot A: Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 140:1785–1794. 2011. View Article : Google Scholar : PubMed/NCBI
5	Solberg IC, Lygren I, Jahnsen J, Aadland E, Høie O, Cvancarova M, Bernklev T, Henriksen M, Sauar J, Vatn MH, et al: Clinical course during the first 10 years of ulcerative colitis: Results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 44:431–440. 2009. View Article : Google Scholar : PubMed/NCBI
6	Sandborn WJ, Feagan BG, Hanauer SB, Lochs H, Löfberg R, Modigliani R, Present DH, Rutgeerts P, Schölmerich J, Stange EF and Sutherland LR: A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 122:512–530. 2002. View Article : Google Scholar : PubMed/NCBI
7	Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, Barakauskiene A, Villanacci V, Von Herbay A, Warren BF, et al: European evidence based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. Gut. 1 55 Suppl:11–15. 2006.
8	Van Assche G, Dignass A, Panes J, Beaugerie L, Karagiannis J, Allez M, Ochsenkühn T, Orchard T, Rogler G, Louis E, et al: The second European evidence-based consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis. 4:7–27. 2010. View Article : Google Scholar : PubMed/NCBI
9	Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D'Haens G, Diamond RH, Broussard DL, et al: Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 362:1383–1395. 2010. View Article : Google Scholar : PubMed/NCBI
10	Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP, et al: Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: A prospective observational cohort study. Lancet. 374:1617–1625. 2009. View Article : Google Scholar : PubMed/NCBI
11	Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P, et al: Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 141:1621–1628.e1-5. 2011. View Article : Google Scholar : PubMed/NCBI
12	Beaugerie L and Sokol H: Clinical, serological and genetic predictors of inflammatory bowel disease course. World J Gastroenterol. 18:3806–3813. 2012. View Article : Google Scholar : PubMed/NCBI
13	Ehsani AH, Mortazavi H, Balighi K, Hosseini MS, Azizpour A, Hejazi SP, Goodarzi A and Darvari SB: Changes in body mass index and lipid profile in psoriatic patients after treatment with standard protocol of infliximab. Acta Med Iran. 54:570–575. 2016.PubMed/NCBI
14	Kopp A, Buechler C, Neumeier M, Weigert J, Aslanidis C, Schölmerich J and Schäffler A: Innate immunity and adipocyte function: Ligand-specific activation of multiple Toll-like receptors modulates cytokine, adipokine, and chemokine secretion in adipocytes. Obesity (Silver Spring). 17:648–656. 2009. View Article : Google Scholar : PubMed/NCBI
15	Schäffler A, Schölmerich J and Salzberger B: Adipose tissue as an immunological organ: Toll-like receptors, C1q/TNFs and CTRPs. Trends Immunol. 28:393–399. 2007. View Article : Google Scholar : PubMed/NCBI
16	Schäffler A and Buechler C: CTRP family: Linking immunity to metabolism. Trends Endocrinol Metab. 23:194–204. 2012. View Article : Google Scholar : PubMed/NCBI
17	Friedman JM and Halaas JL: Leptin and the regulation of body weight in mammals. Nature. 395:763–770. 1998. View Article : Google Scholar : PubMed/NCBI
18	Lennard-Jones JE: Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl. 170:2–6; discussion 16–19. 1989. View Article : Google Scholar : PubMed/NCBI
19	Bruun JM, Pedersen SB, Kristensen K and Richelsen B: Effects of pro-inflammatory cytokines and chemokines on leptin production in human adipose tissue in vitro. Mol Cell Endocrinol. 190:91–99. 2002. View Article : Google Scholar : PubMed/NCBI
20	Kirchgessner TG, Uysal KT, Wiesbrock SM, Marino MW and Hotamisligil GS: Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes. J Clin Invest. 100:2777–2782. 1997. View Article : Google Scholar : PubMed/NCBI
21	Waluga M, Hartleb M, Boryczka G, Kukla M and Zwirska-Korczala K: Serum adipokines in inflammatory bowel disease. World J Gastroenterol. 20:6912–6917. 2014. View Article : Google Scholar : PubMed/NCBI
22	Bernstein CN, Eliakim A, Fedail S, Fried M, Gearry R, Goh KL, Hamid S, Khan AG, Khalif I, Ng SC, et al: World gastroenterology organisation global guidelines inflammatory bowel disease: Update August 2015. J Clin Gastroenterol. 50:803–818. 2016. View Article : Google Scholar : PubMed/NCBI
23	Winawer SJ, Krabshuis J, Lambert R, O'Brien M and Fried M; World Gastroenterology Organization Guidelines Committee, : Cascade colorectal cancer screening guidelines: A global conceptual model. J Clin Gastroenterol. 45:297–300. 2011. View Article : Google Scholar : PubMed/NCBI
24	American Society for Gastrointestinal Endoscopy Standards of Practice Committee, ; Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, Chathadi KV, Decker GA, Early DS, Evans JA, et al: The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 81:1101–1121.e1-13. 2015. View Article : Google Scholar : PubMed/NCBI
25	Travis SP, Schnell D, Krzeski P, Abreu MT, Altman DG, Colombel JF, Feagan BG, Hanauer SB, Lémann M, Lichtenstein GR, et al: Developing an instrument to assess the endoscopic severity of ulcerative colitis: The Ulcerative colitis endoscopic index of severity (UCEIS). Gut. 61:535–542. 2012. View Article : Google Scholar : PubMed/NCBI
26	D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, Lémann M, Marteau P, Rutgeerts P, Schölmerich J and Sutherland LR: A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 132:763–786. 2007. View Article : Google Scholar : PubMed/NCBI
27	Barnes EL and Burakoff R: New biomarkers for diagnosing inflammatory bowel disease and assessing treatment outcomes. Inflamm Bowel Dis. 22:2956–2965. 2016. View Article : Google Scholar : PubMed/NCBI
28	Wang P, Mariman E, Renes J and Keijer J: The secretory function of adipocytes in the physiology of white adipose tissue. J Cell Physiol. 216:3–13. 2008. View Article : Google Scholar : PubMed/NCBI
29	Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J and Feve B: Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 17:4–12. 2006.PubMed/NCBI
30	Sobhani I, Bado A, Vissuzaine C, Buyse M, Kermorgant S, Laigneau JP, Attoub S, Lehy T, Henin D, Mignon M and Lewin MJ: Leptin secretion and leptin receptor in the human stomach. Gut. 47:178–183. 2000. View Article : Google Scholar : PubMed/NCBI
31	Karmiris K, Koutroubakis IE, Xidakis C, Polychronaki M, Voudouri T and Kouroumalis EA: Circulating levels of leptin, adiponectin, resistin, and ghrelin in inflammatory bowel disease. Inflamm Bowel Dis. 12:100–105. 2006. View Article : Google Scholar : PubMed/NCBI
32	Tuzun A, Uygun A, Yesilova Z, Ozel AM, Erdil A, Yaman H, Bagci S, Gulsen M, Karaeren N and Dagalp K: Leptin levels in the acute stage of ulcerative colitis. J Gastroenterol Hepatol. 19:429–432. 2004. View Article : Google Scholar : PubMed/NCBI
33	Ballinger A, Kelly P, Hallyburton E, Besser R and Farthing M: Plasma leptin in chronic inflammatory bowel disease and HIV: Implications for the pathogenesis of anorexia and weight loss. Clin Sci (Lond). 94:479–483. 1998. View Article : Google Scholar : PubMed/NCBI
34	Hoppin AG, Kaplan LM, Zurakowski D, Leichtner AM and Bousvaros A: Serum leptin in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 26:500–505. 1998. View Article : Google Scholar : PubMed/NCBI
35	Barbier M, Vidal H, Desreumaux P, Dubuquoy L, Bourreille A, Colombel JF, Cherbut C and Galmiche JP: Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol Clin Biol. 27:987–991. 2003.PubMed/NCBI
36	Paul G, Schäffler A, Neumeier M, Fürst A, Bataillle F, Buechler C, Müller-Ladner U, Schölmerich J, Rogler G and Herfarth H: Profiling adipocytokine secretion from creeping fat in Crohn's disease. Inflamm Bowel Dis. 12:471–477. 2006. View Article : Google Scholar : PubMed/NCBI
37	Franchimont D, Roland S, Gustot T, Quertinmont E, Toubouti Y, Gervy MC, Deviere J and Van Gossum A: Impact of infliximab on serum leptin levels in patients with Crohn's disease. J Clin Endocrinol Metab. 90:3510–3516. 2005. View Article : Google Scholar : PubMed/NCBI
38	Bennett BD, Solar GP, Yuan JQ, Mathias J, Thomas GR and Matthews W: A role for leptin and its cognate receptor in hematopoiesis. Curr Biol. 6:1170–1180. 1996. View Article : Google Scholar : PubMed/NCBI
39	Togo M, Tsukamoto K, Satoh H, Hara M, Futamura A, Nakarai H, Nakahara K and Hashimoto Y: Relationship between levels of leptin and hemoglobin in Japanese men. Blood. 93:4444–4445. 1999.PubMed/NCBI